Document is current
Any future updates will be listed below
-
Authors
Ferrada, Luciano https://orcid.org/0000-0001-5478-2325
Barahona, María José
Vera, Matías
Stockwell, Brent R. https://orcid.org/0000-0002-3532-3868
Nualart, Francisco https://orcid.org/0000-0002-7762-1417
-
Funding
Funding for this research was provided by:
Fondo Nacional de Desarrollo Científico y Tecnológico (11200335, 3210076, 1221147)
Ministry of Education, Government of Chile | National Commission for Scientific and Technological Research | Fondo de Fomento al Desarrollo Científico y Tecnológico (VIU-22P0021)
Center for Strategic Scientific Initiatives, National Cancer Institute (R35CA209896)
- License Information
-
More Information
Article History
Received: 27 February 2023
Revised: 7 September 2023
Accepted: 13 September 2023
First Online: 27 September 2023
Competing interests
: BRS is an inventor on patents and patent applications involving ferroptosis; co-founded and serves as a consultant to ProJenX, Inc. and Exarta Therapeutics; holds equity in Sonata Therapeutics; serves as a consultant to Weatherwax Biotechnologies Corporation and Akin Gump Strauss Hauer & Feld LLP; and receives sponsored research support from Sumitomo Dainippon Pharma Oncology. The other authors declare no competing interests.
: All the experiments were reviewed and approved by the bioethics committee of the Universidad de Concepción.
